The Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International Federation

References

• Aguilar Martinez P, Angastiniotis M, Eleftheriou A, et al. Haemoglobinopathies in Europe: health & migration policy perspectives. Orphanet J Rare Dis. 2014;9:97.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Kattamis A, Fragodimitri C, et al. National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol. 2019;98(1):55–66.
   PubMed Web of Science ®Google Scholar
• Ansari-Moghaddam A, Adineh HA, Zareban I, et al. The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran. Epidemiol Health. 2018;40:e2018048.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia. 3rd ed. TIF Publication no. 20. Nicosia (Cyprus): Thalassaemia International Federation; 2014.
   Google Scholar
• Angastiniotis M, Eleftheriou A, Galanello R, et al. (editors). Prevention of thalassaemias and other haemoglobin disorders: volume 1: principles [Internet]. 2nd ed. Nicosia (Cyprus): Thalassaemia International Federation; 2013.
   Google Scholar
• Silvestroni E, Bianco I. Screening for microcytemia in Italy: analysis of data collected in the past 30 years. Am J Genet. 1975;27(2):198–212.
   Web of Science ®Google Scholar
• Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962;2(5319):1577–1580.
   PubMed Web of Science ®Google Scholar
• Silvestroni E, Bianco I, Graziani B, et al. First premarital screening of thalassaemia carriers in intermediate schools in Latium. J Med Genet. 1978;15(3):202–207.
   PubMed Web of Science ®Google Scholar
• Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet. 1981;1(8216):369–371.
   PubMed Web of Science ®Google Scholar
• Angastiniotis M, Kyriakidou S, Hadjiminas M. The Cyprus thalassaemia control program. Birth Defects Orig Artic Ser. 1988;23(5B):417–432.
   PubMedGoogle Scholar
• Cao A, Galanello R, Melis MA, et al. Our experience in screening and genetic counseling for beta-thalassemia. Minerva Med. 1981;72(10):623–628.
   PubMed Web of Science ®Google Scholar
• Barrai I, Vullo C. Screening for beta-thalassaemia heterozygotes. Lancet. 1980;2(8206):1257.
   PubMed Web of Science ®Google Scholar
• Fairweather DV, Modell B, Berdoukas V, et al. Antenatal diagnosis of thalassaemia major. Br Med J. 1978;1(6109):350–353.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hereditary Diseases Programme. Guidelines for the control of haemoglobin disorders. Modell B, editor. World Health Organization, 1994 [cited December 31 2020]. Available from: https://apps.who.int/iris/handle/10665/66665.
   Google Scholar
• Fletcher JC, Berg K, Tranøy KE. Ethical aspects of medical genetics. A proposal for guidelines in genetic counseling, prenatal diagnosis and screening. Clin Genet. 1985;27(2):199–205.
   PubMed Web of Science ®Google Scholar
• Modell B. The ethics of prenatal diagnosis and genetic counselling. World Health Forum. 1990;11(2):179–186.
   PubMedGoogle Scholar
• Cappellini MD, Porter JB, Viprakasit V, et al. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies? Blood Rev. 2018;32(4):300–311.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006;91(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86(4):332–338.
   PubMed Web of Science ®Google Scholar
• Rowley PT, Loader S, Sutera CJ, et al. Prenatal genetic counseling for hemoglobinopathy carriers: a comparison of primary providers of prenatal care and professional genetic counselors. Am J Hum Genet. 1995;56(3):769–776.
   PubMed Web of Science ®Google Scholar
• Petrou M. Informed choice in a multi-cultural world. Thal Rep. 2018;8(1):7475.
   Google Scholar
• Modell B, Khan M, Darlison M, et al. A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ. 2001;79(11):1006–1013.
   PubMed Web of Science ®Google Scholar
• Modell B. Ethical aspects of genetic screening. Ann Med. 1992;24(6):549–555.
   PubMed Web of Science ®Google Scholar
• Ebrahim S, Raza AZ, Hussain M, et al. Knowledge and beliefs regarding thalassemia in an urban population. Cureus. 2019;11(7):e5268.
   PubMed Web of Science ®Google Scholar
• Al-Farsi OA, Al-Farsi YM, Gupta I, et al. A study on knowledge, attitude, and practice towards premarital carrier screening among adults attending primary healthcare centers in a region in Oman. BMC Public Health. 2014;14:380
   PubMed Web of Science ®Google Scholar
• Ngim CF, Ibrahim H, Lai NM, et al. A single centre study on birth of children with transfusion-dependent thalassaemia in Malaysia and reasons for ineffective prevention. Prenat Diagn. 2015;35(1):51–59.
   PubMed Web of Science ®Google Scholar
• Olwi DI, Merdad LA, Ramadan EK. Thalassemia: a prevalent disease yet unknown term among college students in Saudi Arabia. J Community Genet. 2018;9(3):277–282.
   PubMed Web of Science ®Google Scholar
• Petrou M. Screening for beta thalassaemia. Indian J Hum Genet. 2010;16(1):1–5.
   PubMedGoogle Scholar
• Schmidt RM. Hemoglobinopathy screening: approaches to diagnosis, education and counseling. Am J Public Health. 1974;64(8):799–804.
   PubMed Web of Science ®Google Scholar
• Kyriakides T. The formation of the Cypriot Thalasasemia prevention system: the ‘slow’ assembly and construction of a problem (1944–1984). J Hist Sociol. 2020;33(2):234–247.
   Web of Science ®Google Scholar
• Weil LG, Charlton MR, Coppinger C, et al. Sickle cell disease and thalassaemia antenatal screening programme in England over 10 years: a review from 2007/2008 to 2016/2017. J Clin Pathol. 2020;73(4):183–190.
   PubMed Web of Science ®Google Scholar
• Loader S, Sutera CJ, Walden M, et al. Prenatal screening for hemoglobinopathies II. Evaluation of counselling. Am J Hum Genet. 1991;48(3):447–451.
   PubMed Web of Science ®Google Scholar
• Ormond EK, Laurino MY, Barlow-Stewart K, et al. Genetic counseling globally: where are we now? Am J Med Genet C Semin Med Genet. 2018;178(1):98–107.
   PubMed Web of Science ®Google Scholar
• Al-Matary A, Ali J. Controversies and considerations regarding the termination of pregnancy for foetal anomalies in Islam. BMC Med Ethics. 2014;15:10.
   PubMed Web of Science ®Google Scholar
• Alsaeed ES, Farhat GN, Assiri AM, et al. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. J Epidemiol Glob Health. 2017;7(S1):S41–S47.
   PubMed Web of Science ®Google Scholar
• Alkhaldi SM, Khatatbeh MM, Berggren VE, et al. Knowledge and attitudes toward mandatory premarital screening among university students in North Jordan. Hemoglobin. 2016;40(2):118–124.
   PubMed Web of Science ®Google Scholar
• Hamamy H, Antonarakis SE, Cavalli-Sforza LL, et al. Consanguineous marriages, pearls and perils: Geneva International Consanguinity Workshop Report. Genet Med. 2011;13(9):841–847.
   PubMed Web of Science ®Google Scholar
• Islam MM, Ababneh FM, Khan MHR. Consanguineous marriage in Jordan: an update. J Biosoc Sci. 2018;50(4):573–578.
   PubMed Web of Science ®Google Scholar
• Hamamy H, Jamhawi L, Al-Darawsheh J, et al. Consanguineous marriages in Jordan: why is the rate changing with time? Clin Genet. 2005;67(6):511–516.
   PubMed Web of Science ®Google Scholar
• Na'amnih W, Romano-Zelekha O, Kabaha A, et al. Continuous decrease of consanguineous marriages among Arabs in Israel. Am J Hum Biol. 2015;27(1):94–98.
   PubMed Web of Science ®Google Scholar
• Modell B, Ward RHT, Fairweather DVI. Effect of introducing antenatal diagnosis on the reproductive behaviour of families at risk for thalassaemia. Br Med J. 1980;280 (6228):1347–1350.
   PubMed Web of Science ®Google Scholar
• Cao A, Rosatelli MC, Galanello R. Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp. 1996;197:137–151.
   PubMedGoogle Scholar
• Loukopoulos D. Haemoglobinopathies in Greece: prevention programme over the past 35 years. Indian J Med Res. 2011;134(4):572–576.
   PubMedGoogle Scholar
• Hadipour Dehshal M, Tabrizi Namini M, Ahmadvand A, et al. Evaluation of the national prevention program in Iran, 2007–2009: the accomplishments and challenges with reflections on the path ahead. Hemoglobin. 2014;38(3):179–187.
   PubMed Web of Science ®Google Scholar
• Giambona A, Damiani G, Vinciguerra M, et al. Incidence of haemoglobinopathies in Sicily: the impact of screening and prenatal diagnosis. Int J Clin Pract. 2015;69(10):1129–1138.
   PubMed Web of Science ®Google Scholar
• Ladis V, Karagiorga-Lagana M, Tsatra I, et al. Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation. Eur J Haematol. 2013;90(4):313–322.
   PubMed Web of Science ®Google Scholar
• Galton F. Eugenics: its definition, scope, and aims. Am J Sociol. 1904;10(1):1–25.
   Google Scholar
• World Health Organizatin. Advisory Committee on Health Research. Genomics and world health: report of the Advisory Committee on Health Research; 2002 [cited December 31 2020]. Available from: https://apps.who.int/iris/handle/10665/42453.
   Google Scholar